OUR SCIENCE
Targeting Cancer's Metabolic Dependency
Cancer is not only a genetic disease—it is a metabolic one. Cancer cells reprogram nutrient transport and intracellular metabolism to support uncontrolled proliferation, survival under stress, and resistance to therapy.
At METRUVA Therapeutics, we focus on identifying and disrupting these metabolic vulnerabilities.
Scientific Leadership
Our team combines expertise in:
-
Cancer metabolism
-
Transporter biology
-
Small-molecule medicinal chemistry
-
Translational oncology
Clinical development and regulatory strategy
The Metabolic Shift in Cancer
Malignant cells alter:
-
Nutrient transporter expression
-
Glycolytic and alternative sugar utilization pathways
-
Mitochondrial bioenergetics
-
Redox balance
-
Anabolic biosynthesis
These adaptations create targetable liabilities that are distinct from normal tissue metabolism.
Our programs are designed to selectively interrupt cancer-specific fuel pathways while minimizing systemic toxicity.
Platform Expansion
Our discovery platform enables:
-
Identification of new metabolic targets
-
Rapid small-molecule optimization
-
Scalable clinical translation
Why Metabolic Targeting Matters
Targeting cancer metabolism offers the potential to:
-
Overcome resistance mechanisms
-
Enhance combination therapy strategies
-
Improve durability of response
-
Reduce systemic toxicity
We believe the next frontier in oncology lies in rational metabolic intervention.
Development Strategy
Our clinical development approach emphasizes:
-
Biomarker-enriched patient populations
-
Early signal detection
-
Rational combination therapy strategies
-
Clear regulatory pathway planning
Our Scientific Strategy
1. Identify Cancer-Specific Metabolic Dependencies
-
We leverage molecular profiling, metabolic flux analysis, and tumor subtype characterization to pinpoint critical nutrient transport and utilization pathways.
2. Design First-in-Class Small Molecules
-
Our discovery engine focuses on highly selective inhibitors targeting key metabolic drivers.
3. Integrate Biomarker Strategy Early
-
We embed biomarker development into preclinical and clinical programs to:
-
Enable patient stratification
-
Confirm target engagement
-
Support regulatory alignment
4. Translate with Precision
-
Our development model emphasizes exposure-response relationships, mechanistic validation, and clinically meaningful endpoints.
Contact
Like what you see? Get in touch to learn more.
